Peter A. McSweeney, MD, discusses challenges with implementing chimeric antigen receptorT-cell therapy in some community oncology practices.
Peter A. McSweeney, MD, hematologist/oncologist at the Colorado Blood cancer Institute, discusses challenges with implementing chimeric antigen receptor (CAR) T-cell therapy in some community oncology practices.
There are large and small community oncology practices, explains McSweeney. Larger centers often have the resource to administer CAR T-cell therapy the way it is done in academic centers. For small community practices, giving CAR T-cell therapy usually requires a referral to an academic center.
The key challenge in the way of small community practices is the lack of infrastructure, according to McSweeney.
Transcript:
0:07 | Community practices come in different types. There are some quite large community malignancy programs, which are actually really clinically the equivalent of academic centers. And so, they handle all this pretty much according the same algorithms as the academic centers. The issue of you know, smaller oncology practices in this area really is, you know, not an issue right now. There's been very little penetration of CAR T-cell therapy, and these types of cellular therapies to those practices, although they are subtly showing interest in trying to develop capability.
0:44 | The biggest challenges for administering these CAR T cells in the community are developing a program that has the appropriate expertise and infrastructure for this type of work. And it's a very multifaceted type of therapy draws on inpatient and outpatient arrangements that meet the needs of the patients. And also the is a need for subspecialty support in the hospital for patients who have complications with the therapy.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More